Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT05876000

Corheart 6 LVAS Study

Led by Shenzhen Core Medical Technology CO.,LTD. · Updated on 2026-01-08

53

Participants Needed

11

Research Sites

371 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The primary objective of this study is to evaluate the safety and effectiveness of the Corheart 6 LVAS when used for the treatment of advanced left ventricular heart failure in a European population at 6 months post-implantation. The secondary objective is to assess the long-term safety and effectiveness of Corheart 6 LVAS treatment.

CONDITIONS

Official Title

Corheart 6 LVAS Study

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older and 75 years or younger
  • Signed informed consent form
  • Body Surface Area (BSA) of 1.2 m2 or greater
  • New York Heart Association (NYHA) Class IV heart failure
  • Left Ventricular Ejection Fraction (LVEF) of 25% or less
  • Despite optimal medical treatment, patients must have one or more of the following: unable to exercise for heart failure, or if able, peak VO2 less than 12 mL/kg/min or less than 50% predicted; progressive end-organ dysfunction due to reduced perfusion; use of Impella or IABP devices; or inotrope dependence or inability to wean from inotropes
Not Eligible

You will not qualify if you...

  • Heart failure treatable with other therapies like CRT or CRT-D
  • Intolerance to anticoagulant, antiplatelet, or other required therapies
  • Known hypo- or hypercoagulable states such as disseminated intravascular coagulation or heparin-induced thrombocytopenia type II
  • Platelet count less than 100,000/ml
  • Psychiatric disorders, irreversible cognitive dysfunction, or psychosocial issues impairing compliance
  • Technical obstacles posing high surgical risk
  • Active, uncontrolled infection
  • Severe end-organ dysfunction or failure risk factors including: high bilirubin, ischemic hepatitis, liver cirrhosis, severe COPD, fixed pulmonary hypertension unresponsive to treatment, recent stroke or significant carotid artery disease, severe kidney dysfunction or dialysis, significant peripheral vascular disease
  • Heart failure due to uncorrected thyroid disease, certain cardiomyopathies, pericardial disease, amyloidosis, or giant cell myocarditis
  • Uncorrected moderate to severe aortic insufficiency without plans for correction during implant
  • History of untreated large abdominal or thoracic aortic aneurysm
  • Uncontrollable ventricular arrhythmias
  • Recent STEMI within 2 weeks before implantation
  • Right ventricular failure defined by specific echocardiographic and hemodynamic criteria
  • Planned Bi-VAD support before enrollment
  • Recent cardiac arrest without full cognitive recovery
  • History of organ transplant
  • Low pre-albumin or albumin levels
  • Any condition other than heart failure limiting survival to less than 24 months
  • Positive pregnancy test if of childbearing potential
  • Lactating mothers
  • Participation in other conflicting clinical trials
  • Placement in an institution by court or authorities order

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 11 locations

1

Universitätsklinikum Graz

Graz, Austria

Not Yet Recruiting

2

Universitätskliniken der MedUni Wien

Vienna, Austria

Actively Recruiting

3

Herz-und Diabeteszentrum Nordrhein-Westfalen

Bad Oeynhausen, Germany

Actively Recruiting

4

Deutsches Herzzentrum der Charité

Berlin, Germany

Actively Recruiting

5

Klinikum Links der Weser

Bremen, Germany

Not Yet Recruiting

6

Universitätsklinikum Hamburg

Hamburg, Germany

Actively Recruiting

7

Universitätsklinikums Heidelberg

Heidelberg, Germany

Actively Recruiting

8

Herzzentrum Leipzig

Leipzig, Germany

Actively Recruiting

9

Universitätsklinikum Würzburg

Würzburg, Germany

Not Yet Recruiting

10

IRCCS Ospedale San Raffaele

Milan, Italy

Not Yet Recruiting

11

Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino

Torino, Italy

Not Yet Recruiting

Loading map...

Research Team

X

Xiaoli Shi

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here